StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-12 | $67.31 | $65.58 | -2.57% | 0.9M |
| 05-13 | $65.10 | $62.69 | -3.71% | 0.8M |
| 05-14 | $62.46 | $62.19 | -0.43% | 0.5M |
| 05-15 | $62.19 | $63.15 | +1.54% | 0.4M |
| 05-18 | $63.13 | $58.74 | -6.95% | 0.5M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
No sell-side coverage available for ANAB.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Fundamentals not available for ANAB.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $25.56M | $234.60M | $126.35M | $50.03M |
Operating Income | $-34.64M | $47.90M | $-19.00M | $-53.71M |
Net Income | $-52.88M | $-13.23M | $-62.85M | $-38.63M |
EPS (Diluted) | $-1.84 | $-0.46 | $-2.16 | $-2.62 |
Total Assets | $329.68M | $364.39M | $353.10M | $335.25M |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $248.47M | $238.20M | $109.83M | $44.30M |
Free Cash Flow OCF − CapEx | $-25.94M | $19.61M | $-78.39M | $-51.02M |
Shares Outstanding | 29.03M | 28.02M | 27.58M | 27.97M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.